FDA Panel Rejects Lipocine's Testosterone Pill Post author:Sam Post published:January 10, 2018 Post category:BioPharma The FDA voted six in favor and thirteen against the benefit/risk profile of TLANDO. Source: BioSpace You Might Also Like Novartis AG Lays Out R&D Game Plan at Meet and Greet With 30 Execs in Boston May 31, 2017 <b>EBS Technologies</b> Appoints <b>Karl Schweitzer</b> As Chief Executive Officer August 27, 2017 BASi Names Senior Vice President Of Preclinical Services March 8, 2017
